Literature DB >> 11096711

Multiple Sclerosis: Symptomatic Treatment.

C T Bever1.   

Abstract

Therapy for multiple sclerosis (MS) that prevents exacerbation of the disease and slows the progression of disability has not diminished the importance of treating symptoms. Because the new agents are not curative and rarely reverse existing deficits, many patients under treatment have or will have persistent symptoms. Many neurologic symptoms are seen in patients with MS, but it is important to recognize that some nonneurologic symptoms, such as pain, fatigue, and mood disturbance, are common and may cause significant disability. The first and most important step in the management of symptoms is to discuss the symptoms with the patient on an ongoing basis. The second step is to recognize treatable symptoms and to apply the appropriate strategies for management. There have been promising results with experimental agents, primarily potassium channel blockers, that may improve function in demyelin-ated fiber pathways and that offer the possibility of treatment for a range of symptoms. At present, the management of symptoms varies, depending on the symptom, and it involves the coordinated application of a range of treatment approaches including medication, lifestyle changes, rehabilitation, and, in some cases, surgery.

Entities:  

Year:  1999        PMID: 11096711     DOI: 10.1007/s11940-999-0005-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  23 in total

1.  Primidone as a treatment for cerebellar tremor in multiple sclerosis--two case reports.

Authors:  Y Henkin; Y O Herishanu
Journal:  Isr J Med Sci       Date:  1989-12

2.  Penile prosthesis for impotence in multiple sclerosis.

Authors:  E W Massey; A B Pleet
Journal:  Ann Neurol       Date:  1979-11       Impact factor: 10.422

3.  Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor.

Authors:  G P Rice; J Lesaux; P Vandervoort; L Macewan; G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

4.  Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation.

Authors:  C Geny; J P Nguyen; B Pollin; A Feve; F Ricolfi; P Cesaro; J D Degos
Journal:  Mov Disord       Date:  1996-09       Impact factor: 10.338

5.  The effect of mechanical damping loads on disabling action tremor.

Authors:  M L Aisen; A Arnold; I Baiges; S Maxwell; M Rosen
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

6.  Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications.

Authors:  J G Blaivas; K B Labib; S J Michalik; A A Zayed
Journal:  J Urol       Date:  1980-08       Impact factor: 7.450

7.  Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.

Authors:  R G Feldman; M Kelly-Hayes; J P Conomy; J M Foley
Journal:  Neurology       Date:  1978-11       Impact factor: 9.910

8.  Erectile dysfunction in multiple sclerosis.

Authors:  H J Kirkeby; E U Poulsen; T Petersen; J Dørup
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

9.  The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.

Authors:  H A van Diemen; C H Polman; T M van Dongen; A C van Loenen; J J Nauta; M J Taphoorn; H K van Walbeek; J C Koetsier
Journal:  Ann Neurol       Date:  1992-08       Impact factor: 10.422

10.  Impact of aerobic training on fitness and quality of life in multiple sclerosis.

Authors:  J H Petajan; E Gappmaier; A T White; M K Spencer; L Mino; R W Hicks
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.